These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28107606)

  • 21. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
    Fajkovic H; Mathieu R; Lucca I; Hiess M; Hübner N; Al Hussein Al Awamlh B; Lee R; Briganti A; Karakiewicz P; Lotan Y; Roupret M; Rink M; Kluth L; Loidl W; Seitz C; Klatte T; Kramer G; Susani M; Shariat SF
    Urol Oncol; 2016 May; 34(5):233.e1-6. PubMed ID: 26973136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study.
    Lughezzani G; Lazzeri M; Buffi NM; Abrate A; Mistretta FA; Hurle R; Pasini L; Castaldo L; Zandegiacomo De Zorzi S; Peschechera R; Fiorini G; Taverna G; Casale P; Guazzoni G
    Urol Oncol; 2015 Aug; 33(8):337.e7-14. PubMed ID: 26055430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
    Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
    Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
    Pérez-Martínez FC; Alonso V; Sarasa JL; Manzarbeitia F; Vela-Navarrete R; Calahorra FJ; Esbrit P
    Histol Histopathol; 2008 Jun; 23(6):709-15. PubMed ID: 18366009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
    Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
    Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
    Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.
    Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG
    BJU Int; 2017 Nov; 120(5):651-658. PubMed ID: 28371244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer.
    Aaltomaa S; Lipponen P; Tammi R; Tammi M; Viitanen J; Kankkunen JP; Kosma VM
    Urol Int; 2002; 69(4):266-72. PubMed ID: 12444281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAGI-2 downregulation: a potential predictor of tumor progression and early recurrence in Han Chinese patients with prostate cancer.
    Cao Z; Ji J; Wang FB; Kong C; Xu H; Xu YL; Chen X; Yu YW; Sun YH
    Asian J Androl; 2020; 22(6):616-622. PubMed ID: 32167077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
    Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
    Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP database.
    Park YH; Kim Y; Yu H; Choi IY; Byun SS; Kwak C; Chung BH; Lee HM; Kim CS; Lee JY
    Sci Rep; 2016 May; 6():25419. PubMed ID: 27146602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.